Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study
Year: 2025
Type: article
Study design: Observational Study
Abstract: A retrospective study of extranodal natural killer/T-cell lymphoma (ENKL) patients diagnosed between 2014 and 2021 in Japan was conducted. Among 351 patients with sufficient data, 116 (33%) were in the advanced stage (5 in stage III and 111 in stage IV) at diagnosis, and were further analyzed. The median age was 60 years (range: 19-90), and 68 (59%) were male. Ninety-four (85%) of stage IV patients had two or more extranodal involvements. The most common first-line regimen was SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide; 52%). The 2-year overall survival (OS) for all patients was 38.5%, which was significantly improved after 2017 (25.2% for 2014-2017 vs. 50.7% for 2018-2021; P = 0.008). Patients treated with SMILE showed better OS than those treated with DeVIC or CHOP (2y-OS: 57.1%, 35.8%, and 0%, respectively; P < 0.001). The prognosis was significantly better in patients who received hematopoietic stem cell transplantation (HSCT) than in those who did not (2-year OS: 68.3% vs. 17.6%, P < 0.001). Multivariate analysis showed SMILE and HSCT were significant factors for OS. In conclusion, the prognosis of advanced-stage ENKL has improved in recent years. The L-asparaginase-containing chemotherapy and subsequent HSCT is considered the recommended strategy.
Source: Leukemia
Institutions: Shimane University, Mie University, Mie University Hospital, Kobe University Hospital, Kyoto Prefectural University of Medicine, National Cancer Center Hospital, Dokkyo Medical University, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Saitama Cancer Center, Kurashiki Central Hospital, Niigata University, Kobe City Medical Center General Hospital, Chiba Cancer Center, Kanagawa Cancer Center, Tohoku University Hospital, Nagano Prefectural Suzaka Hospital
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
Funders: Nihon University, Kagoshima University, Kanazawa University, Ministry of Education, Culture, Sports, Science and Technology, Dokkyo Medical University, Kanazawa Medical University, Shimane University, University of Fukui, Hokkaido University, Fujita Health University, Jikei University School of Medicine, Kawasaki Medical School, Japan Society for the Promotion of Science
OpenAlex ID: W4407635289
